

**EU Cancer Mission conference
4 December 2025, Copenhagen, Denmark**

"Advancing cancer care: focus on personalised treatment and innovation for all Europeans"

Transforming lives through research, innovation and equitable access

Venue: Scandic Hotel Copenhagen

Format: Hybrid event with simultaneous interpretation (EN/DA)

Background

The EU Cancer Mission conference will take place in Copenhagen on 4 December 2025, marking the second event of the EU Cancer Mission's communication and stakeholder engagement campaign. Building on the successful Warsaw conference, which focused on prevention, screening and quality of life, the Copenhagen event will concentrate on the complementary pillars of the Mission: advanced diagnostics, cutting-edge treatment modalities, and the implementation of personalised medicine in clinical practice.

This event takes place during Denmark's presidency of the Council of the European Union, aligning with the country's commitment to health innovation, evidence-based healthcare policy, and equal access to advanced cancer care.

The conference will showcase how the EU Cancer Mission is delivering real-world diagnostics and treatment decisions that benefit patients across all EU Member States and Associated Countries. With a particular focus on clinical implementation and patient outcomes, the event will discuss how innovation (e.g. liquid biopsy, immunotherapy, metabolic targeting, and integrated diagnostics, etc) is improving survival rates and quality of life while ensuring no one is left behind.

The timing is particularly significant as many EU Cancer Mission projects are quite advanced and generate concrete clinical data. This creates a unique opportunity to present concrete results, share lessons learned, and chart the path forward for precision cancer medicine in Europe.

Objectives

The Copenhagen event will:

- **Diagnostic innovation:** Showcase how EU-funded research in liquid biopsy, molecular profiling, and biomarker discovery has the potential to transform cancer detection and treatment, with concrete examples of clinical implementation across EU Member States

- **Treatment breakthroughs:** Showcase next-generation therapies emerging from EU Cancer Mission projects, including personalized immunotherapy, metabolic targeting, and novel drug combinations, with evidence of improved patient outcomes and survival rates
- **Bridge research to clinic:** Present successful models for translating laboratory discoveries into routine cancer care, featuring molecular tumour boards, clinical trial networks, and real-world implementation strategies that can be replicated across Europe
- **Equitable implementation:** Discuss how to address barriers to accessing precision diagnostics and targeted treatments, sharing best practices for overcoming geographic and socioeconomic disparities while building capacity in all EU regions
- **Strengthened European networks:** Facilitate new collaborations between leading cancer centres, emerging research groups, and industry partners, aiming to leverage complementary expertise.

Time	Session	Description
08:30-09:00	Registration and welcome coffee	Networking and exhibition viewing
09:00-09:30	Opening ceremony and keynote addresses	Institutional welcomes and keynote addresses • Joanna Drake, Deputy Director-General, DG RTD, European Commission
09:30-09:45	The EU Cancer Mission Approach	An overview of the EU Cancer Mission Approach • Annika Nowak, Head of Sector, Cancer Mission Secretariat, European Commission • Andrea Elisabeth Rudolph, Danish cancer survivor and patient advocate cancer survivor
09:45-10:45	Panel 1: From Detection to Decision: Cutting-Edge Diagnostics in Precision Cancer Care	This session will showcase groundbreaking diagnostic innovations that are fundamentally transforming personalised cancer care across Europe. Distinguished experts will present cutting-edge advances in AI-enhanced molecular imaging, liquid biopsies, and comprehensive multi-omic

		profiling technologies, demonstrating how these revolutionary tools are reshaping early detection paradigms, optimising treatment stratification, and enabling precise real-time disease monitoring • Prof. Andreas Kjær, University of Copenhagen & Rigshospitalet (Denmark) • Dr. Maria Carla Parrini, Institut Curie, EU Cancer Mission ARTURO Project lead (France) • Dr. Holm Graessner, European Rare Diseases Research Alliance (ERDERA) • Prof. Klaus Pantel, University Medical Center Hamburg-Eppendorf
10:45-11:15	Coffee break	Coffee Break & Poster Viewing Session 1
11:15-11:35	Presentations 1	Rapid-fire presentations of EU Cancer Mission projects (5 min each) • FORCE “Fostering Oncology Research by Charities in Europe”: Nancy Abou-Zeid, Foundation ARC (Belgium) • MULTIR “Molecular and clinical profiling to guide treatment of bladder cancer”: Prof. Harald Mischak • PragmaTIL Mission Cancer project: Dr. Vladimir Galvao de Aguiar
11:35-12:35	Panel 2: Cancer Immunology and Biomarkers of Immunotherapy	This panel will explore cutting-edge approaches to decode the complex dialogue between tumors and the immune system, presenting validated biomarkers that are transforming clinical decision-making • Prof. Marek Svoboda, Masaryk University, EU Cancer Mission Board Member (Czechia)

		• Dr. Robert Aleksandrowicz, Cellis (Poland) • Prof. Nicolai Juul Birkbak, Aarhus University (Denmark)
12:35-14:00	Lunch break and extended poster session	Lunch Break & Poster Viewing Session 2
14:00-14:20	Presentations 2	Rapid-fire presentations of EU Cancer Mission projects (5 min each) • MONALISA “Liquid Biopsy–Based Monitoring of Relapsed Neuroblastoma in Children — Early Detection and Digital Decision Support”: Dr. Marie Bernkopf • Integrating Multi-Omic Biomarkers and Citizen Engagement in Colorectal Cancer Diagnosis : Dr. Silvia Marsoni • CARE1 “A European Study on First-Line Treatment of Metastatic Kidney Cancer”; Gustave Roussy Institute (France): Maia Claveau
14:20:15:20	Panel 3: Cancer Metabolism and Novel Therapeutic Targets	The panel will explore how precision medicine is transitioning from research environments to routine clinical application across healthcare systems in Europe • Dr. Sara Sdelci, Centre for Genomic Regulation (Spain)
15:20-15:50	Coffee break and Poster presentation	Coffee break and Poster presentation 3
15:50-16:50	Panel 4: Holistic Approaches to Precision Medicine	This session will tackle the complex challenge of integrating multi-dimensional data streams to create truly personalized cancer treatment strategies. Moving beyond single-gene or single-modality approaches, this panel will demonstrate how comprehensive data integration—spanning genomics, transcriptomics, proteomics, metabolomics, and clinical imaging—enables superior treatment selection and patient outcomes

		• Dr Bettina Ryll, Melanoma Patient Network Europe, ECHoS member (Sweden) • Prof. Maria A. Blasco, National Cancer Research Centre (CNIO) (Spain) • Prof. Kjetil Taskén, Oslo University Hospital Comprehensive Cancer Centre , Scientific leader of EU Cancer Mission Project PRIME-ROSE (Norway) • Dr Rodrigo Dienstmann, Principal Investigator of the Oncology Data Science Group of Vall d'Hebron Institute of Oncology.
16:50-17:00	Closing remarks	Institutional and moderator's closing remarks.
17:00-18:30	Networking reception	
18:30	End	